AbbVie’s Rinvoq (upadacitinib) Met Primary and Secondary Endpoints in P-III SELECT-AXIS 2 Clinical Trial for Non-Radiographic Axial Spondyloarthritis

 AbbVie’s Rinvoq (upadacitinib) Met Primary and Secondary Endpoints in P-III SELECT-AXIS 2 Clinical Trial for Non-Radiographic Axial Spondyloarthritis

Shots:

  • Study 2 of the P-III SELECT-AXIS 2 clinical trial evaluates the efficacy & safety of upadacitinib (qd, 15mg) vs PBO in 314 adults with active nr-axSpA
  • The trial met its 1EPs of ASAS40 response & 2EPs @14wks., patients achieved ASAS40 response & ASDAS low disease activity (45% vs 23%) & (42% vs 18%), reductions in signs & symptoms including back pain & inflammation, improvements in physical function (-2.61 vs -1.47) @14wks.
  • Additionally, improvement in MRI SPARCC score (-2.49 vs 0.57); mean change from baseline in patient’s assessment of total back pain (-2.91 vs -2.00), safety data were consistent with previous studies & known safety profile of the therapy, no new risks were observed

Click here to read full press release/ article | Ref: AbbVie | Image: Fierce Biotech

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post